$6.33
-0.10 (-1.56%)
Open$6.42
Previous Close$6.43
Day High$6.59
Day Low$6.27
52W High$7.60
52W Low$4.52
Volume—
Avg Volume14.3K
Market Cap57.44M
P/E Ratio—
EPS$-0.11
SectorBiotechnology
Analyst Ratings
Strong Buy
7 analysts
Price Target
-32.5% upside
Current
$6.33
$6.33
Target
$4.27
$4.27
$3.74
$4.27 avg
$6.64
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 26.98M | 23.63M | 25.83M |
| Net Income | -1,014,911 | -799,982 | 1.23M |
| Profit Margin | -3.8% | -3.6% | 4.8% |
| EBITDA | -1,004,339 | -835,629 | 1.46M |
| Free Cash Flow | — | — | 1.13M |
| Rev Growth | +14.2% | +14.2% | +0.8% |
| Debt/Equity | 0.38 | 0.38 | 0.10 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $214.98 | -1.15% | 166.6 | 397.77B |
| AMGN | Amgen Inc | $353.28 | +0.41% | 24.7 | 190.40B |
| GILD | Gilead Sciences Inc | $140.30 | +0.67% | 19.6 | 166.66B |
| VRTX | Vertex Pharmaceuticals Inc | $447.26 | +0.16% | 29.1 | 114.87B |
| REGN | Regeneron Pharmaceuticals | $777.25 | +0.60% | 17.9 | 80.50B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.73 | -0.65% | 139.7 | 43.84B |